Sanofi caps insulin at $35 per month

17 Mar 2023
www.pharmamanufacturing.com
Sanofi announced this week that it will be slashing the list price of its most widely prescribed insulin, Lantus, by 78%, and its short-acting Apidra by 70%.
According to Sanofi, with the price discounts, no insured patient will pay more than $35 out of pocket for insulin. The new prices will go into effect January 1, 2024.
Last year, Sanofi launched its unbranded biologic for Lantus at 60% less than the branded list price. But, according to Olivier Bogillot, Sanofi's head of U.S. General Medicines, inherent structural challenges prevented the U.S. health system from taking advantage of the discount.
Now Sanofi is joining other drugmakers like Eli Lilly who are providing hefty discounts to both their biosimilars and branded insulins.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.